[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"tldr","before":"\"Once the most aggressive subtype, now one of the most treatable thanks to trastuzumab and, more recently, Enhertu.\"","after":"\"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu.\""}]},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"standardOfCare","before":"[\n      { setting: \"Early stage\", approach: \"Neoadjuvant THP or T-DXd → surgery → trastuzumab/pertuzumab (pCR) or T-DXd/T-DM1 (residual).\", refs: [\"trastuzumab\", \"trastuzumab-deruxtecan\", \"trastuzumab-emtansine\", \"des...","after":"[\n      { setting: \"Early stage\", approach: \"Neoadjuvant THP or T-DXd → surgery → trastuzumab/pertuzumab (pCR) or T-DXd/T-DM1 (residual).\", refs: [\"trastuzumab\", \"trastuzumab-deruxtecan\", \"trastuzumab-emtansine\", \"des..."}]},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","commit":"815a2a8bae","date":"2026-09-05","author":"Jude Gomila","message":"OnCo: open map of oncology — corpus (642 objects, 14 kinds), graph, static site, API, TNBC spike","file":"src/data/cancers.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"group"},{"field":"wikipedia"},{"field":"burden"},{"field":"tldr"},{"field":"summary"},{"field":"biomarkers"},{"field":"standardOfCare"},{"field":"stateOfArt"},{"field":"history"},{"field":"pipeline"},{"field":"openProblems"},{"field":"targets"},{"field":"technologies"},{"field":"pathways"},{"field":"tags"}]}]